Perrigo Company plc Payments for (Proceeds from) Derivative Instrument, Investing Activities
Perrigo Company plc (PRGO) reported Payments for (Proceeds from) Derivative Instrument, Investing Activities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities · last filed 2026-02-26
- Perrigo Company plc payments for (proceeds from) derivative instrument, investing activities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Perrigo Company plc payments for (proceeds from) derivative instrument, investing activities for fiscal 2024 was $48.20M.
- Perrigo Company plc payments for (proceeds from) derivative instrument, investing activities for fiscal 2023 was $0.00.
- Perrigo Company plc payments for (proceeds from) derivative instrument, investing activities for fiscal 2022 was -$61.70M.
| Period end | Payments for (Proceeds from) Derivative Instrument, Investing Activities 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $48.20M 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2022-12-31 | -$61.70M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |